Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.77 |
| ▸ | MAOB | P27338 | 16/20 | 0.77 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532440 | 0.88 | MAOA (0.70) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| SCHEMBL13674790 | 0.88 | MAOA (0.77) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| SCHEMBL14290978 | 0.88 | MAOA (0.77) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| SCHEMBL10034856 | 0.88 | MAOA (0.77) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| SCHEMBL29623853 | 0.87 | MAOA (1.00) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| SCHEMBL936291 | 0.87 | MAOA (1.00) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL2640267 | 0.86 | MAOA (0.97) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| Water SCHEMBL2640298 | 0.86 | MAOA (0.97) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL2640254 | 0.85 | MAOA (0.95) | MAOAMAOBNCOA3CYP11B1CYP11B2 | |
| SCHEMBL2241505 | 0.84 | MAOA (0.72) | MAOAMAOBNCOA3CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066653-B1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM SPA (IT) | 2012-09-12 | — | — | EP | disclosed |
| US-8193353-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A (IT) | 2012-06-05 | — | — | US | disclosed |
| US-8193353-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A (IT) | 2012-06-05 | — | — | US | disclosed |
| US-20110257209-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110257209-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A (IT) | 2011-10-20 | — | — | US | disclosed |
| US-7994181-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A. (IT) | 2011-08-09 | — | — | US | disclosed |
| US-7994181-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A. (IT) | 2011-08-09 | — | — | US | disclosed |
| US-20090264451-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-10-22 | — | — | US | disclosed |
| US-20090264451-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-10-22 | — | — | US | disclosed |
| WO-2008014822-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264451-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | IL1A, IL6, IL1B | MAOA 3094/4885MAOB 3506/4885NCOA3 276/4885 |
| US-20110257209-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | IL1A, IL6, IL1B | MAOA 3149/4885MAOB 3479/4885NCOA3 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.